http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022119535-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_019b20edeffde7485f350d157f011feb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2278 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2021-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_601f84d33e7a374b1a84d2fd49b8f3d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a73e4d51bd2c51d1777e008beb601d9c |
| publicationDate | 2022-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022119535-A1 |
| titleOfInvention | New dosage regimen for inhaled vasoactive intestinal polypeptide |
| abstract | The present invention relates to new improved and effective administration regimen of aviptadil in order to reduce and eliminate the risks of nebulization treatment and to protect both patient relatives and healthcare workers especially in pandemic conditions such as Covid-19. Here, said dosage regimen of aviptadil for use in the treatment of lung diseases in a subject in need by thereof aims to reduce the dosing frequency. Accordingly, aviptadil is administered at least 2 times in a day and wherein the period between the administrations does not exceed 200 minutes. |
| priorityDate | 2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.